Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

COVID Reference, 4th edition, 372 pages

+ the daily Top 10

  Breast Cancer

  Free Subscription

Articles published in Breast Cancer Res

Retrieve available abstracts of 330 articles:
HTML format

Single Articles

    September 2020
  1. CABEL L, Rosenblum D, Lerebours F, Brain E, et al
    Plasma thymidine kinase 1 activity and outcome of ER+ HER2- metastatic breast cancer patients treated with palbociclib and endocrine therapy.
    Breast Cancer Res. 2020;22:98.
    PubMed     Abstract available

  2. JAGER A, de Vries EGE, der Houven van Oordt CWM, Neven P, et al
    A phase 1b study evaluating the effect of elacestrant treatment on estrogen receptor availability and estradiol binding to the estrogen receptor in metastatic breast cancer lesions using (18)F-FES PET/CT imaging.
    Breast Cancer Res. 2020;22:97.
    PubMed     Abstract available

  3. BERTRAND KA, Bethea TN, Gerlovin H, Coogan PF, et al
    Aspirin use and risk of breast cancer in African American women.
    Breast Cancer Res. 2020;22:96.
    PubMed     Abstract available

    August 2020
  4. LO GULLO R, Daimiel I, Rossi Saccarelli C, Bitencourt A, et al
    MRI background parenchymal enhancement, fibroglandular tissue, and mammographic breast density in patients with invasive lobular breast cancer on adjuvant endocrine hormonal treatment: associations with survival.
    Breast Cancer Res. 2020;22:93.
    PubMed     Abstract available

  5. KLEMENT RJ, Champ CE, Kammerer U, Koebrunner PS, et al
    Impact of a ketogenic diet intervention during radiotherapy on body composition: III-final results of the KETOCOMP study for breast cancer patients.
    Breast Cancer Res. 2020;22:94.
    PubMed     Abstract available

  6. BERNHARDT SM, Dasari P, Wrin J, Raymond W, et al
    Discordance in 21-gene recurrence scores between paired breast cancer samples is inversely associated with patient age.
    Breast Cancer Res. 2020;22:90.
    PubMed     Abstract available

  7. VAN GEELEN CT, Savas P, Teo ZL, Luen SJ, et al
    Clinical implications of prospective genomic profiling of metastatic breast cancer patients.
    Breast Cancer Res. 2020;22:91.
    PubMed     Abstract available

  8. CHAO X, Liu L, Sun P, Yang X, et al
    Immune parameters associated with survival in metaplastic breast cancer.
    Breast Cancer Res. 2020;22:92.
    PubMed     Abstract available

  9. O'BRIEN NA, McDermott MSJ, Conklin D, Luo T, et al
    Targeting activated PI3K/mTOR signaling overcomes acquired resistance to CDK4/6-based therapies in preclinical models of hormone receptor-positive breast cancer.
    Breast Cancer Res. 2020;22:89.
    PubMed     Abstract available

  10. DIAZ-SANTANA MV, O'Brien KM, D'Aloisio AA, Regalado G, et al
    Perinatal and postnatal exposures and risk of young-onset breast cancer.
    Breast Cancer Res. 2020;22:88.
    PubMed     Abstract available

  11. NANOU A, Zeune LL, Bidard FC, Pierga JY, et al
    HER2 expression on tumor-derived extracellular vesicles and circulating tumor cells in metastatic breast cancer.
    Breast Cancer Res. 2020;22:86.
    PubMed     Abstract available

  12. PORTMAN N, Milioli HH, Alexandrou S, Coulson R, et al
    MDM2 inhibition in combination with endocrine therapy and CDK4/6 inhibition for the treatment of ER-positive breast cancer.
    Breast Cancer Res. 2020;22:87.
    PubMed     Abstract available

  13. LI L, Lin L, Veeraraghavan J, Hu Y, et al
    Therapeutic role of recurrent ESR1-CCDC170 gene fusions in breast cancer endocrine resistance.
    Breast Cancer Res. 2020;22:84.
    PubMed     Abstract available

  14. BIGANZOLI L, Cinieri S, Berardi R, Pedersini R, et al
    EFFECT: a randomized phase II study of efficacy and impact on function of two doses of nab-paclitaxel as first-line treatment in older women with advanced breast cancer.
    Breast Cancer Res. 2020;22:83.
    PubMed     Abstract available

    July 2020
  15. LIPS EH, Benard-Slagter A, Opdam M, Scheerman CE, et al
    BRCAness digitalMLPA profiling predicts benefit of intensified platinum-based chemotherapy in triple-negative and luminal-type breast cancer.
    Breast Cancer Res. 2020;22:79.
    PubMed     Abstract available

  16. MCGEE EE, Kim CH, Wang M, Spiegelman D, et al
    Erythrocyte membrane fatty acids and breast cancer risk by tumor tissue expression of immuno-inflammatory markers and fatty acid synthase: a nested case-control study.
    Breast Cancer Res. 2020;22:78.
    PubMed     Abstract available

  17. MADIGAN LI, Dinh P, Graham JD
    Neoadjuvant endocrine therapy in locally advanced estrogen or progesterone receptor-positive breast cancer: determining the optimal endocrine agent and treatment duration in postmenopausal women-a literature review and proposed guidelines.
    Breast Cancer Res. 2020;22:77.
    PubMed     Abstract available

  18. BONNEAU C, Elies A, Kieffer Y, Bourachot B, et al
    A subset of activated fibroblasts is associated with distant relapse in early luminal breast cancer.
    Breast Cancer Res. 2020;22:76.
    PubMed     Abstract available

  19. ASPERGER H, Stamm N, Gierke B, Pawlak M, et al
    Progesterone receptor membrane component 1 regulates lipid homeostasis and drives oncogenic signaling resulting in breast cancer progression.
    Breast Cancer Res. 2020;22:75.
    PubMed     Abstract available

  20. EMAD A, Ray T, Jensen TW, Parat M, et al
    Superior breast cancer metastasis risk stratification using an epithelial-mesenchymal-amoeboid transition gene signature.
    Breast Cancer Res. 2020;22:74.
    PubMed     Abstract available

    June 2020
  21. TERKELSEN T, Russo F, Gromov P, Haakensen VD, et al
    Secreted breast tumor interstitial fluid microRNAs and their target genes are associated with triple-negative breast cancer, tumor grade, and immune infiltration.
    Breast Cancer Res. 2020;22:73.
    PubMed     Abstract available

  22. BYERLY JH, Port ER, Irie HY
    PRKCQ inhibition enhances chemosensitivity of triple-negative breast cancer by regulating Bim.
    Breast Cancer Res. 2020;22:72.
    PubMed     Abstract available

  23. BLOHMER M, Zhu L, Atkinson JM, Beriwal S, et al
    Patient treatment and outcome after breast cancer orbital and periorbital metastases: a comprehensive case series including analysis of lobular versus ductal tumor histology.
    Breast Cancer Res. 2020;22:70.
    PubMed     Abstract available

  24. FINLAY-SCHULTZ J, Jacobsen BM, Riley D, Paul KV, et al
    New generation breast cancer cell lines developed from patient-derived xenografts.
    Breast Cancer Res. 2020;22:68.
    PubMed     Abstract available

  25. GUO H, Ding Q, Gong Y, Gilcrease MZ, et al
    Comparison of three scoring methods using the FDA-approved 22C3 immunohistochemistry assay to evaluate PD-L1 expression in breast cancer and their association with clinicopathologic factors.
    Breast Cancer Res. 2020;22:69.
    PubMed     Abstract available

  26. BERGQVIST M, Elebro K, Sandsveden M, Borgquist S, et al
    Effects of tumor-specific CAP1 expression and body constitution on clinical outcomes in patients with early breast cancer.
    Breast Cancer Res. 2020;22:67.
    PubMed     Abstract available

  27. ROBERTS MS, Anstine LJ, Finke VS, Bryson BL, et al
    KLF4 defines the efficacy of the epidermal growth factor receptor inhibitor, erlotinib, in triple-negative breast cancer cells by repressing the EGFR gene.
    Breast Cancer Res. 2020;22:66.
    PubMed     Abstract available

  28. MALINIAK ML, Cheriyan AM, Sherman ME, Liu Y, et al
    Detection of crown-like structures in breast adipose tissue and clinical outcomes among African-American and White women with breast cancer.
    Breast Cancer Res. 2020;22:65.
    PubMed     Abstract available

  29. GU X, Wang B, Zhu H, Zhou Y, et al
    Age-associated genes in human mammary gland drive human breast cancer progression.
    Breast Cancer Res. 2020;22:64.
    PubMed     Abstract available

  30. BAKER LA, Holliday H, Roden D, Krisp C, et al
    Proteogenomic analysis of Inhibitor of Differentiation 4 (ID4) in basal-like breast cancer.
    Breast Cancer Res. 2020;22:63.
    PubMed     Abstract available

  31. YIN L, Duan JJ, Bian XW, Yu SC, et al
    Triple-negative breast cancer molecular subtyping and treatment progress.
    Breast Cancer Res. 2020;22:61.
    PubMed     Abstract available

  32. HUMPHRIES BA, Cutter AC, Buschhaus JM, Chen YC, et al
    Enhanced mitochondrial fission suppresses signaling and metastasis in triple-negative breast cancer.
    Breast Cancer Res. 2020;22:60.
    PubMed     Abstract available

    May 2020
  33. ONISHI N, Sadinski M, Hughes MC, Ko ES, et al
    Ultrafast dynamic contrast-enhanced breast MRI may generate prognostic imaging markers of breast cancer.
    Breast Cancer Res. 2020;22:58.
    PubMed     Abstract available

  34. CLATOT F, Perdrix A, Beaussire L, Lequesne J, et al
    Risk of early progression according to circulating ESR1 mutation, CA-15.3 and cfDNA increases under first-line anti-aromatase treatment in metastatic breast cancer.
    Breast Cancer Res. 2020;22:56.
    PubMed     Abstract available

  35. SUTTON EJ, Onishi N, Fehr DA, Dashevsky BZ, et al
    A machine learning model that classifies breast cancer pathologic complete response on MRI post-neoadjuvant chemotherapy.
    Breast Cancer Res. 2020;22:57.
    PubMed     Abstract available

  36. VUAGNAT P, Frelaut M, Ramtohul T, Basse C, et al
    COVID-19 in breast cancer patients: a cohort at the Institut Curie hospitals in the Paris area.
    Breast Cancer Res. 2020;22:55.
    PubMed     Abstract available

  37. KIM HJ, Noh WC, Lee ES, Jung YS, et al
    Efficacy of neoadjuvant endocrine therapy compared with neoadjuvant chemotherapy in pre-menopausal patients with oestrogen receptor-positive and HER2-negative, lymph node-positive breast cancer.
    Breast Cancer Res. 2020;22:54.
    PubMed     Abstract available

  38. GOLDSTEIN LJ, Perez RP, Yardley D, Han LK, et al
    Correction to: A window-of-opportunity trial of the CXCR1/2 inhibitor reparixin in operable HER-2-negative breast cancer.
    Breast Cancer Res. 2020;22:52.
    PubMed     Abstract available

  39. JAYARAMAN S, Hou X, Kuffel MJ, Suman VJ, et al
    Antitumor activity of Z-endoxifen in aromatase inhibitor-sensitive and aromatase inhibitor-resistant estrogen receptor-positive breast cancer.
    Breast Cancer Res. 2020;22:51.
    PubMed     Abstract available

  40. KONAN HP, Kassem L, Omarjee S, Surmieliova-Garnes A, et al
    ERalpha-36 regulates progesterone receptor activity in breast cancer.
    Breast Cancer Res. 2020;22:50.
    PubMed     Abstract available

  41. AL-ANSARI MM, Al-Saif M, Arafah M, Eldali AM, et al
    Clinical and functional significance of tumor/stromal ATR expression in breast cancer patients.
    Breast Cancer Res. 2020;22:49.
    PubMed     Abstract available

  42. SKRIVER SK, Jensen MB, Knoop AS, Ejlertsen B, et al
    Tumour-infiltrating lymphocytes and response to neoadjuvant letrozole in patients with early oestrogen receptor-positive breast cancer: analysis from a nationwide phase II DBCG trial.
    Breast Cancer Res. 2020;22:46.
    PubMed     Abstract available

  43. KOLBERG-LIEDTKE C, Oleg G, Fred H, Friedrich F, et al
    Association of TILs with clinical parameters, Recurrence Score(R) results, and prognosis in patients with early HER2-negative breast cancer (BC)-a translational analysis of the prospective WSG PlanB trial.
    Breast Cancer Res. 2020;22:47.
    PubMed     Abstract available

  44. MARTINEZ-SAEZ O, Chic N, Pascual T, Adamo B, et al
    Frequency and spectrum of PIK3CA somatic mutations in breast cancer.
    Breast Cancer Res. 2020;22:45.
    PubMed     Abstract available

  45. GALLAGHER EJ, Fei K, Feldman SM, Port E, et al
    Insulin resistance contributes to racial disparities in breast cancer prognosis in US women.
    Breast Cancer Res. 2020;22:40.
    PubMed     Abstract available

  46. GOLE L, Yeong J, Lim JCT, Ong KH, et al
    Quantitative stain-free imaging and digital profiling of collagen structure reveal diverse survival of triple negative breast cancer patients.
    Breast Cancer Res. 2020;22:42.
    PubMed     Abstract available

  47. PEREZ KERKVLIET C, Dwyer AR, Diep CH, Oakley RH, et al
    Glucocorticoid receptors are required effectors of TGFbeta1-induced p38 MAPK signaling to advanced cancer phenotypes in triple-negative breast cancer.
    Breast Cancer Res. 2020;22:39.
    PubMed     Abstract available

    April 2020
  48. BEN HASSEN C, Gutierrez-Pajares JL, Guimaraes C, Guibon R, et al
    Apolipoprotein-mediated regulation of lipid metabolism induces distinctive effects in different types of breast cancer cells.
    Breast Cancer Res. 2020;22:38.
    PubMed     Abstract available

  49. VAN MARCKE C, Helaers R, De Leener A, Merhi A, et al
    Tumor sequencing is useful to refine the analysis of germline variants in unexplained high-risk breast cancer families.
    Breast Cancer Res. 2020;22:36.
    PubMed     Abstract available

  50. MCKNIGHT BN, Kim S, Boerner JL, Viola NT, et al
    Cetuximab PET delineated changes in cellular distribution of EGFR upon dasatinib treatment in triple negative breast cancer.
    Breast Cancer Res. 2020;22:37.
    PubMed     Abstract available

  51. HAIDER MT, Saito H, Zarrer J, Uzhunnumpuram K, et al
    Breast cancer bone metastases are attenuated in a Tgif1-deficient bone microenvironment.
    Breast Cancer Res. 2020;22:34.
    PubMed     Abstract available

  52. VERNIERI C, Corti F, Nichetti F, Ligorio F, et al
    Everolimus versus alpelisib in advanced hormone receptor-positive HER2-negative breast cancer: targeting different nodes of the PI3K/AKT/mTORC1 pathway with different clinical implications.
    Breast Cancer Res. 2020;22:33.
    PubMed     Abstract available

    March 2020
  53. CHAUDHARY P, Gibbs LD, Maji S, Lewis CM, et al
    Correction to: Serum exosomal-annexin A2 is associated with African-American triple-negative breast cancer and promotes angiogenesis.
    Breast Cancer Res. 2020;22:31.
    PubMed     Abstract available

  54. QIU SQ, van Rooijen J, Nienhuis HH, van der Vegt B, et al
    High hepatocyte growth factor expression in primary tumor predicts better overall survival in male breast cancer.
    Breast Cancer Res. 2020;22:30.
    PubMed     Abstract available

  55. ETTL J, Im SA, Ro J, Masuda N, et al
    Hematologic adverse events following palbociclib dose reduction in patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: pooled analysis from randomized phase 2 and 3 studies.
    Breast Cancer Res. 2020;22:27.
    PubMed     Abstract available

  56. ZUNDELEVICH A, Dadiani M, Kahana-Edwin S, Itay A, et al
    Correction to: ESR1 mutations are frequent in newly diagnosed metastatic and loco-regional recurrence of endocrine-treated breast cancer and carry worse prognosis.
    Breast Cancer Res. 2020;22:28.
    PubMed     Abstract available

    February 2020
  57. MAVADDAT N, Antoniou AC, Mooij TM, Hooning MJ, et al
    Correction to: Risk-reducing salpingo-oophorectomy, natural menopause, and breast cancer risk: an international prospective cohort of BRCA1 and BRCA2 mutation carriers.
    Breast Cancer Res. 2020;22:25.
    PubMed     Abstract available

  58. GRANT WB
    Lower vitamin D status may help explain why black women have a higher risk of invasive breast cancer than white women.
    Breast Cancer Res. 2020;22:24.

  59. LE CORNET C, Walter B, Sookthai D, Johnson TS, et al
    Circulating 27-hydroxycholesterol and breast cancer tissue expression of CYP27A1, CYP7B1, LXR-beta, and ERbeta: results from the EPIC-Heidelberg cohort.
    Breast Cancer Res. 2020;22:23.
    PubMed     Abstract available

  60. VAKLAVAS C, Roberts BS, Varley KE, Lin NU, et al
    TBCRC 002: a phase II, randomized, open-label trial of preoperative letrozole with or without bevacizumab in postmenopausal women with newly diagnosed stage 2/3 hormone receptor-positive and HER2-negative breast cancer.
    Breast Cancer Res. 2020;22:22.
    PubMed     Abstract available

  61. YANES T, Young MA, Meiser B, James PA, et al
    Clinical applications of polygenic breast cancer risk: a critical review and perspectives of an emerging field.
    Breast Cancer Res. 2020;22:21.
    PubMed     Abstract available

  62. BODICOAT DH, Schoemaker MJ, Jones ME, McFadden E, et al
    Correction to: Timing of pubertal stages and breast cancer risk: the Breakthrough Generations Study.
    Breast Cancer Res. 2020;22:19.
    PubMed     Abstract available

  63. GIARDIELLO D, Antoniou AC, Mariani L, Easton DF, et al
    Letter to the editor: a response to Ming's study on machine learning techniques for personalized breast cancer risk prediction.
    Breast Cancer Res. 2020;22:17.

  64. ZUNDELEVICH A, Dadiani M, Kahana-Edwin S, Itay A, et al
    ESR1 mutations are frequent in newly diagnosed metastatic and loco-regional recurrence of endocrine-treated breast cancer and carry worse prognosis.
    Breast Cancer Res. 2020;22:16.
    PubMed     Abstract available

    January 2020
  65. PANCHOLI S, Leal MF, Ribas R, Simigdala N, et al
    Correction to: Combination of mTORC1/2 inhibitor vistusertib plus fulvestrant in vitro and in vivo targets oestrogen receptor-positive endocrine-resistant breast cancer.
    Breast Cancer Res. 2020;22:14.
    PubMed     Abstract available

  66. DE RUIJTER TC, van der Heide F, Smits KM, Aarts MJ, et al
    Prognostic DNA methylation markers for hormone receptor breast cancer: a systematic review.
    Breast Cancer Res. 2020;22:13.
    PubMed     Abstract available

  67. CHAUDHARY P, Gibbs LD, Maji S, Lewis CM, et al
    Serum exosomal-annexin A2 is associated with African-American triple-negative breast cancer and promotes angiogenesis.
    Breast Cancer Res. 2020;22:11.
    PubMed     Abstract available

  68. JACOBS SA, Robidoux A, Abraham J, Perez-Garcia JM, et al
    Correction to: NSABP FB-7: a phase II randomized neoadjuvant trial with paclitaxel + trastuzumab and/or neratinib followed by chemotherapy and postoperative trastuzumab in HER2+ breast cancer.
    Breast Cancer Res. 2020;22:9.
    PubMed     Abstract available

  69. WENNSTIG AK, Wadsten C, Garmo H, Fredriksson I, et al
    Long-term risk of ischemic heart disease after adjuvant radiotherapy in breast cancer: results from a large population-based cohort.
    Breast Cancer Res. 2020;22:10.
    PubMed     Abstract available

  70. MAVADDAT N, Antoniou AC, Mooij TM, Hooning MJ, et al
    Risk-reducing salpingo-oophorectomy, natural menopause, and breast cancer risk: an international prospective cohort of BRCA1 and BRCA2 mutation carriers.
    Breast Cancer Res. 2020;22:8.
    PubMed     Abstract available

  71. LEWIS K, Kiepas A, Hudson J, Senecal J, et al
    p66ShcA functions as a contextual promoter of breast cancer metastasis.
    Breast Cancer Res. 2020;22:7.
    PubMed     Abstract available

  72. HEATH AK, Muller DC, van den Brandt PA, Papadimitriou N, et al
    Nutrient-wide association study of 92 foods and nutrients and breast cancer risk.
    Breast Cancer Res. 2020;22:5.
    PubMed     Abstract available

  73. GOLDSTEIN LJ, Perez RP, Yardley D, Han LK, et al
    A window-of-opportunity trial of the CXCR1/2 inhibitor reparixin in operable HER-2-negative breast cancer.
    Breast Cancer Res. 2020;22:4.
    PubMed     Abstract available

  74. WANG D, Naydenov NG, Dozmorov MG, Koblinski JE, et al
    Anillin regulates breast cancer cell migration, growth, and metastasis by non-canonical mechanisms involving control of cell stemness and differentiation.
    Breast Cancer Res. 2020;22:3.
    PubMed     Abstract available

    December 2019
  75. GAO Q, Lopez-Knowles E, Cheang MCU, Morden J, et al
    Impact of aromatase inhibitor treatment on global gene expression and its association with antiproliferative response in ER+ breast cancer in postmenopausal patients.
    Breast Cancer Res. 2019;22:2.
    PubMed     Abstract available

  76. MACPHERSON IR, Spiliopoulou P, Rafii S, Saggese M, et al
    A phase I/II study of epertinib plus trastuzumab with or without chemotherapy in patients with HER2-positive metastatic breast cancer.
    Breast Cancer Res. 2019;22:1.
    PubMed     Abstract available

  77. NEDERLOF I, De Bortoli D, Bareche Y, Nguyen B, et al
    Comprehensive evaluation of methods to assess overall and cell-specific immune infiltrates in breast cancer.
    Breast Cancer Res. 2019;21:151.
    PubMed     Abstract available

  78. FERNANDEZ-GARCIA D, Hills A, Page K, Hastings RK, et al
    Plasma cell-free DNA (cfDNA) as a predictive and prognostic marker in patients with metastatic breast cancer.
    Breast Cancer Res. 2019;21:149.
    PubMed     Abstract available

  79. WAN L, Liu T, Hong Z, Pan Y, et al
    NEDD4 expression is associated with breast cancer progression and is predictive of a poor prognosis.
    Breast Cancer Res. 2019;21:148.
    PubMed     Abstract available

  80. SNODERLY HT, Boone BA, Bennewitz MF
    Neutrophil extracellular traps in breast cancer and beyond: current perspectives on NET stimuli, thrombosis and metastasis, and clinical utility for diagnosis and treatment.
    Breast Cancer Res. 2019;21:145.
    PubMed     Abstract available

  81. PATEL HK, Tao N, Lee KM, Huerta M, et al
    Elacestrant (RAD1901) exhibits anti-tumor activity in multiple ER+ breast cancer models resistant to CDK4/6 inhibitors.
    Breast Cancer Res. 2019;21:146.
    PubMed     Abstract available

  82. GIARDIELLO D, Steyerberg EW, Hauptmann M, Adank MA, et al
    Prediction and clinical utility of a contralateral breast cancer risk model.
    Breast Cancer Res. 2019;21:144.
    PubMed     Abstract available

  83. LI CH, Karantza V, Aktan G, Lala M, et al
    Current treatment landscape for patients with locally recurrent inoperable or metastatic triple-negative breast cancer: a systematic literature review.
    Breast Cancer Res. 2019;21:143.
    PubMed     Abstract available

  84. SINN BV, Weber KE, Schmitt WD, Fasching PA, et al
    Human leucocyte antigen class I in hormone receptor-positive, HER2-negative breast cancer: association with response and survival after neoadjuvant chemotherapy.
    Breast Cancer Res. 2019;21:142.
    PubMed     Abstract available

  85. GOLDHAMMER N, Kim J, Timmermans-Wielenga V, Petersen OW, et al
    Characterization of organoid cultured human breast cancer.
    Breast Cancer Res. 2019;21:141.
    PubMed     Abstract available

  86. SHEN Q, Joud A, Schelin MEC, Sjolander A, et al
    Psychiatric disorders and cardiovascular diseases during the diagnostic workup of potential breast cancer: a population-based cohort study in Skane, Sweden.
    Breast Cancer Res. 2019;21:139.
    PubMed     Abstract available

  87. PANCHOLI S, Leal MF, Ribas R, Simigdala N, et al
    Combination of mTORC1/2 inhibitor vistusertib plus fulvestrant in vitro and in vivo targets oestrogen receptor-positive endocrine-resistant breast cancer.
    Breast Cancer Res. 2019;21:135.
    PubMed     Abstract available

  88. DAVIS AA, Zhang Q, Gerratana L, Shah AN, et al
    Association of a novel circulating tumor DNA next-generating sequencing platform with circulating tumor cells (CTCs) and CTC clusters in metastatic breast cancer.
    Breast Cancer Res. 2019;21:137.
    PubMed     Abstract available

  89. LEE YJ, Ho SR, Graves JD, Xiao Y, et al
    CGRRF1, a growth suppressor, regulates EGFR ubiquitination in breast cancer.
    Breast Cancer Res. 2019;21:134.
    PubMed     Abstract available

  90. JACOBS SA, Robidoux A, Abraham J, Perez-Garcia JM, et al
    NSABP FB-7: a phase II randomized neoadjuvant trial with paclitaxel + trastuzumab and/or neratinib followed by chemotherapy and postoperative trastuzumab in HER2(+) breast cancer.
    Breast Cancer Res. 2019;21:133.
    PubMed     Abstract available

    November 2019
  91. WYATT GL, Crump LS, Young CM, Wessells VM, et al
    Cross-talk between SIM2s and NFkappaB regulates cyclooxygenase 2 expression in breast cancer.
    Breast Cancer Res. 2019;21:131.
    PubMed     Abstract available

  92. LEFLEY D, Howard F, Arshad F, Bradbury S, et al
    Development of clinically relevant in vivo metastasis models using human bone discs and breast cancer patient-derived xenografts.
    Breast Cancer Res. 2019;21:130.
    PubMed     Abstract available

  93. NA H, Han J, Ka NL, Lee MH, et al
    High expression of NR1D1 is associated with good prognosis in triple-negative breast cancer patients treated with chemotherapy.
    Breast Cancer Res. 2019;21:127.
    PubMed     Abstract available

  94. ZEINOMAR N, Knight JA, Genkinger JM, Phillips KA, et al
    Alcohol consumption, cigarette smoking, and familial breast cancer risk: findings from the Prospective Family Study Cohort (ProF-SC).
    Breast Cancer Res. 2019;21:128.
    PubMed     Abstract available

  95. KENYON E, Westerhuis JJ, Volk M, Hix J, et al
    Ductal tree ablation by local delivery of ethanol prevents tumor formation in an aggressive mouse model of breast cancer.
    Breast Cancer Res. 2019;21:129.
    PubMed     Abstract available

  96. PUNZI S, Balestrieri C, D'Alesio C, Bossi D, et al
    WDR5 inhibition halts metastasis dissemination by repressing the mesenchymal phenotype of breast cancer cells.
    Breast Cancer Res. 2019;21:123.
    PubMed     Abstract available

  97. DANIA V, Liu Y, Ademuyiwa F, Weber JD, et al
    Associations of race and ethnicity with risk of developing invasive breast cancer after lobular carcinoma in situ.
    Breast Cancer Res. 2019;21:120.
    PubMed     Abstract available

  98. JACOT W, Cottu P, Berger F, Dubot C, et al
    Actionability of HER2-amplified circulating tumor cells in HER2-negative metastatic breast cancer: the CirCe T-DM1 trial.
    Breast Cancer Res. 2019;21:121.
    PubMed     Abstract available

  99. LEE JS, Yost SE, Blanchard S, Schmolze D, et al
    Phase I clinical trial of the combination of eribulin and everolimus in patients with metastatic triple-negative breast cancer.
    Breast Cancer Res. 2019;21:119.
    PubMed     Abstract available

  100. JUNG AY, Behrens S, Schmidt M, Thoene K, et al
    Pre- to postdiagnosis leisure-time physical activity and prognosis in postmenopausal breast cancer survivors.
    Breast Cancer Res. 2019;21:117.
    PubMed     Abstract available

    October 2019
  101. BRANDT KR, Scott CG, Miglioretti DL, Jensen MR, et al
    Automated volumetric breast density measures: differential change between breasts in women with and without breast cancer.
    Breast Cancer Res. 2019;21:118.
    PubMed     Abstract available

  102. MORGENROTH A, Tinkir E, Vogg ATJ, Sankaranarayanan RA, et al
    Targeting of prostate-specific membrane antigen for radio-ligand therapy of triple-negative breast cancer.
    Breast Cancer Res. 2019;21:116.
    PubMed     Abstract available

  103. LEE JO, Kang MJ, Byun WS, Kim SA, et al
    Metformin overcomes resistance to cisplatin in triple-negative breast cancer (TNBC) cells by targeting RAD51.
    Breast Cancer Res. 2019;21:115.
    PubMed     Abstract available

  104. FAN M, Xia P, Liu B, Zhang L, et al
    Tumour heterogeneity revealed by unsupervised decomposition of dynamic contrast-enhanced magnetic resonance imaging is associated with underlying gene expression patterns and poor survival in breast cancer patients.
    Breast Cancer Res. 2019;21:112.
    PubMed     Abstract available

  105. VAN UDEN DJP, van Maaren MC, Strobbe LJA, Bult P, et al
    Metastatic behavior and overall survival according to breast cancer subtypes in stage IV inflammatory breast cancer.
    Breast Cancer Res. 2019;21:113.
    PubMed     Abstract available

  106. PARK S, Han Y, Liu Y, Toriola AT, et al
    Adjuvant chemotherapy and survival among patients 70 years of age and younger with node-negative breast cancer and the 21-gene recurrence score of 26-30.
    Breast Cancer Res. 2019;21:110.
    PubMed     Abstract available

    September 2019
  107. ADAMO B, Bellet M, Pare L, Pascual T, et al
    Oral metronomic vinorelbine combined with endocrine therapy in hormone receptor-positive HER2-negative breast cancer: SOLTI-1501 VENTANA window of opportunity trial.
    Breast Cancer Res. 2019;21:108.
    PubMed     Abstract available

  108. REN J, Smid M, Iaria J, Salvatori DCF, et al
    Cancer-associated fibroblast-derived Gremlin 1 promotes breast cancer progression.
    Breast Cancer Res. 2019;21:109.
    PubMed     Abstract available

  109. BATALINI F, Peacock EG, Stobie L, Robertson A, et al
    Li-Fraumeni syndrome: not a straightforward diagnosis anymore-the interpretation of pathogenic variants of low allele frequency and the differences between germline PVs, mosaicism, and clonal hematopoiesis.
    Breast Cancer Res. 2019;21:107.
    PubMed     Abstract available

  110. LEITHNER D, Horvat JV, Marino MA, Bernard-Davila B, et al
    Radiomic signatures with contrast-enhanced magnetic resonance imaging for the assessment of breast cancer receptor status and molecular subtypes: initial results.
    Breast Cancer Res. 2019;21:106.
    PubMed     Abstract available

  111. BARROW MA, Martin ME, Coffey A, Andrews PL, et al
    A functional role for the cancer disparity-linked genes, CRYbetaB2 and CRYbetaB2P1, in the promotion of breast cancer.
    Breast Cancer Res. 2019;21:105.
    PubMed     Abstract available

  112. MANI C, Jonnalagadda S, Lingareddy J, Awasthi S, et al
    Prexasertib treatment induces homologous recombination deficiency and synergizes with olaparib in triple-negative breast cancer cells.
    Breast Cancer Res. 2019;21:104.
    PubMed     Abstract available

  113. RIEBENSAHM C, Joosse SA, Mohme M, Hanssen A, et al
    Clonality of circulating tumor cells in breast cancer brain metastasis patients.
    Breast Cancer Res. 2019;21:101.
    PubMed     Abstract available

  114. PATEL TA, Ensor JE, Creamer SL, Boone T, et al
    A randomized, controlled phase II trial of neoadjuvant ado-trastuzumab emtansine, lapatinib, and nab-paclitaxel versus trastuzumab, pertuzumab, and paclitaxel in HER2-positive breast cancer (TEAL study).
    Breast Cancer Res. 2019;21:100.
    PubMed     Abstract available

    August 2019
  115. MIAO Y, Shen Q, Zhang S, Huang H, et al
    Calcium-sensing stromal interaction molecule 2 upregulates nuclear factor of activated T cells 1 and transforming growth factor-beta signaling to promote breast cancer metastasis.
    Breast Cancer Res. 2019;21:99.
    PubMed     Abstract available

  116. RAMANI VC, Lemaire CA, Triboulet M, Casey KM, et al
    Investigating circulating tumor cells and distant metastases in patient-derived orthotopic xenograft models of triple-negative breast cancer.
    Breast Cancer Res. 2019;21:98.
    PubMed     Abstract available

  117. DE GROOT S, Pijl H, Charehbili A, van de Ven S, et al
    Addition of zoledronic acid to neoadjuvant chemotherapy is not beneficial in patients with HER2-negative stage II/III breast cancer: 5-year survival analysis of the NEOZOTAC trial (BOOG 2010-01).
    Breast Cancer Res. 2019;21:97.
    PubMed     Abstract available

  118. TERRY MB, Michels KB, Brody JG, Byrne C, et al
    Environmental exposures during windows of susceptibility for breast cancer: a framework for prevention research.
    Breast Cancer Res. 2019;21:96.
    PubMed     Abstract available

  119. YANG H, Pawitan Y, He W, Eriksson L, et al
    Disease trajectories and mortality among women diagnosed with breast cancer.
    Breast Cancer Res. 2019;21:95.
    PubMed     Abstract available

  120. FOERSTER M, Anderson BO, McKenzie F, Galukande M, et al
    Inequities in breast cancer treatment in sub-Saharan Africa: findings from a prospective multi-country observational study.
    Breast Cancer Res. 2019;21:93.
    PubMed     Abstract available

  121. HUANG CC, Chan SY, Lee WC, Chiang CJ, et al
    Development of a prediction model for breast cancer based on the national cancer registry in Taiwan.
    Breast Cancer Res. 2019;21:92.
    PubMed     Abstract available

  122. NAGPAL A, Redvers RP, Ling X, Ayton S, et al
    Neoadjuvant neratinib promotes ferroptosis and inhibits brain metastasis in a novel syngeneic model of spontaneous HER2(+ve) breast cancer metastasis.
    Breast Cancer Res. 2019;21:94.
    PubMed     Abstract available

  123. ALONZO-PROULX O, Mainprize JG, Harvey JA, Yaffe MJ, et al
    Investigating the feasibility of stratified breast cancer screening using a masking risk predictor.
    Breast Cancer Res. 2019;21:91.
    PubMed     Abstract available

  124. TAN X, Li Z, Ren S, Rezaei K, et al
    Dynamically decreased miR-671-5p expression is associated with oncogenic transformation and radiochemoresistance in breast cancer.
    Breast Cancer Res. 2019;21:89.
    PubMed     Abstract available

  125. HORI A, Shimoda M, Naoi Y, Kagara N, et al
    Vasculogenic mimicry is associated with trastuzumab resistance of HER2-positive breast cancer.
    Breast Cancer Res. 2019;21:88.
    PubMed     Abstract available

  126. HANCOCK BA, Chen YH, Solzak JP, Ahmad MN, et al
    Profiling molecular regulators of recurrence in chemorefractory triple-negative breast cancers.
    Breast Cancer Res. 2019;21:87.
    PubMed     Abstract available

  127. KALLERGI G, Tsintari V, Sfakianakis S, Bei E, et al
    The prognostic value of JUNB-positive CTCs in metastatic breast cancer: from bioinformatics to phenotypic characterization.
    Breast Cancer Res. 2019;21:86.
    PubMed     Abstract available

    July 2019
  128. HUSS L, Butt ST, Borgquist S, Elebro K, et al
    Vitamin D receptor expression in invasive breast tumors and breast cancer survival.
    Breast Cancer Res. 2019;21:84.
    PubMed     Abstract available

  129. KLIMOV S, Miligy IM, Gertych A, Jiang Y, et al
    A whole slide image-based machine learning approach to predict ductal carcinoma in situ (DCIS) recurrence risk.
    Breast Cancer Res. 2019;21:83.
    PubMed     Abstract available

  130. TONSING-CARTER E, Hernandez KM, Kim CR, Harkless RV, et al
    Glucocorticoid receptor modulation decreases ER-positive breast cancer cell proliferation and suppresses wild-type and mutant ER chromatin association.
    Breast Cancer Res. 2019;21:82.
    PubMed     Abstract available

  131. HADA M, Oh H, Pfeiffer RM, Falk RT, et al
    Relationship of circulating insulin-like growth factor-I and binding proteins 1-7 with mammographic density among women undergoing image-guided diagnostic breast biopsy.
    Breast Cancer Res. 2019;21:81.
    PubMed     Abstract available

  132. BASREE MM, Shinde N, Koivisto C, Cuitino M, et al
    Abrupt involution induces inflammation, estrogenic signaling, and hyperplasia linking lack of breastfeeding with increased risk of breast cancer.
    Breast Cancer Res. 2019;21:80.
    PubMed     Abstract available

  133. XING Y, Lin NU, Maurer MA, Chen H, et al
    Phase II trial of AKT inhibitor MK-2206 in patients with advanced breast cancer who have tumors with PIK3CA or AKT mutations, and/or PTEN loss/PTEN mutation.
    Breast Cancer Res. 2019;21:78.
    PubMed     Abstract available

  134. PALOMERAS S, Diaz-Lagares A, Vinas G, Setien F, et al
    Epigenetic silencing of TGFBI confers resistance to trastuzumab in human breast cancer.
    Breast Cancer Res. 2019;21:79.
    PubMed     Abstract available

  135. MCLAUGHLIN RP, He J, van der Noord VE, Redel J, et al
    A kinase inhibitor screen identifies a dual cdc7/CDK9 inhibitor to sensitise triple-negative breast cancer to EGFR-targeted therapy.
    Breast Cancer Res. 2019;21:77.
    PubMed     Abstract available

    June 2019
  136. GREGORY KJ, Roberts AL, Conlon EM, Mayfield JA, et al
    Gene expression signature of atypical breast hyperplasia and regulation by SFRP1.
    Breast Cancer Res. 2019;21:76.
    PubMed     Abstract available

  137. MING C, Viassolo V, Probst-Hensch N, Chappuis PO, et al
    Machine learning techniques for personalized breast cancer risk prediction: comparison with the BCRAT and BOADICEA models.
    Breast Cancer Res. 2019;21:75.
    PubMed     Abstract available

  138. WRIGHT KD, Miller BS, El-Meanawy S, Tsaih SW, et al
    The p52 isoform of SHC1 is a key driver of breast cancer initiation.
    Breast Cancer Res. 2019;21:74.
    PubMed     Abstract available

  139. BOWNES RJ, Turnbull AK, Martinez-Perez C, Cameron DA, et al
    On-treatment biomarkers can improve prediction of response to neoadjuvant chemotherapy in breast cancer.
    Breast Cancer Res. 2019;21:73.
    PubMed     Abstract available

  140. RIMM DL, Han G, Taube JM, Yi ES, et al
    Reanalysis of the NCCN PD-L1 companion diagnostic assay study for lung cancer in the context of PD-L1 expression findings in triple-negative breast cancer.
    Breast Cancer Res. 2019;21:72.
    PubMed     Abstract available

    May 2019
  141. ROSSI L, Biagioni C, McCartney A, Migliaccio I, et al
    Clinical outcomes after palbociclib with or without endocrine therapy in postmenopausal women with hormone receptor positive and HER2-negative metastatic breast cancer enrolled in the TREnd trial.
    Breast Cancer Res. 2019;21:71.
    PubMed     Abstract available

  142. LEE E, Nelson OL, Puyana C, Takita C, et al
    Association between C-reactive protein and radiotherapy-related pain in a tri-racial/ethnic population of breast cancer patients: a prospective cohort study.
    Breast Cancer Res. 2019;21:70.
    PubMed     Abstract available

  143. QUINTELA-FANDINO M, Apala JV, Malon D, Mouron S, et al
    Nintedanib plus letrozole in early breast cancer: a phase 0/I pharmacodynamic, pharmacokinetic, and safety clinical trial of combined FGFR1 and aromatase inhibition.
    Breast Cancer Res. 2019;21:69.
    PubMed     Abstract available

  144. VACHON CM, Scott CG, Tamimi RM, Thompson DJ, et al
    Joint association of mammographic density adjusted for age and body mass index and polygenic risk score with breast cancer risk.
    Breast Cancer Res. 2019;21:68.
    PubMed     Abstract available

  145. SABOL RA, Bowles AC, Cote A, Wise R, et al
    Leptin produced by obesity-altered adipose stem cells promotes metastasis but not tumorigenesis of triple-negative breast cancer in orthotopic xenograft and patient-derived xenograft models.
    Breast Cancer Res. 2019;21:67.
    PubMed     Abstract available

  146. FAN Y, Si W, Ji W, Wang Z, et al
    Rack1 mediates tyrosine phosphorylation of Anxa2 by Src and promotes invasion and metastasis in drug-resistant breast cancer cells.
    Breast Cancer Res. 2019;21:66.
    PubMed     Abstract available

  147. BODELON C, Ambatipudi S, Dugue PA, Johansson A, et al
    Blood DNA methylation and breast cancer risk: a meta-analysis of four prospective cohort studies.
    Breast Cancer Res. 2019;21:62.
    PubMed     Abstract available

  148. JEZEQUEL P, Kerdraon O, Hondermarck H, Guerin-Charbonnel C, et al
    Identification of three subtypes of triple-negative breast cancer with potential therapeutic implications.
    Breast Cancer Res. 2019;21:65.
    PubMed     Abstract available

  149. RAMOVS V, Secades P, Song JY, Thijssen B, et al
    Absence of integrin alpha3beta1 promotes the progression of HER2-driven breast cancer in vivo.
    Breast Cancer Res. 2019;21:63.
    PubMed     Abstract available

  150. WANG Y, Zeng J, Wu W, Xie S, et al
    Nicotinamide N-methyltransferase enhances chemoresistance in breast cancer through SIRT1 protein stabilization.
    Breast Cancer Res. 2019;21:64.
    PubMed     Abstract available

  151. GRINDE MT, Hilmarsdottir B, Tunset HM, Henriksen IM, et al
    Glutamine to proline conversion is associated with response to glutaminase inhibition in breast cancer.
    Breast Cancer Res. 2019;21:61.
    PubMed     Abstract available

  152. LAAKMANN E, Witzel I, Fasching PA, Rezai M, et al
    Development of central nervous system metastases as a first site of metastatic disease in breast cancer patients treated in the neoadjuvant trials GeparQuinto and GeparSixto.
    Breast Cancer Res. 2019;21:60.
    PubMed     Abstract available

  153. PROVANCE OK, Lewis-Wambi J
    Deciphering the role of interferon alpha signaling and microenvironment crosstalk in inflammatory breast cancer.
    Breast Cancer Res. 2019;21:59.
    PubMed     Abstract available

  154. DEMICHELI R, Dillekas H, Straume O, Biganzoli E, et al
    Distant metastasis dynamics following subsequent surgeries after primary breast cancer removal.
    Breast Cancer Res. 2019;21:57.
    PubMed     Abstract available

    April 2019
  155. DOHERTY MR, Parvani JG, Tamagno I, Junk DJ, et al
    The opposing effects of interferon-beta and oncostatin-M as regulators of cancer stem cell plasticity in triple-negative breast cancer.
    Breast Cancer Res. 2019;21:54.
    PubMed     Abstract available

  156. WEBER-LASSALLE N, Borde J, Weber-Lassalle K, Horvath J, et al
    Germline loss-of-function variants in the BARD1 gene are associated with early-onset familial breast cancer but not ovarian cancer.
    Breast Cancer Res. 2019;21:55.
    PubMed     Abstract available

  157. KEHM RD, Hopper JL, John EM, Phillips KA, et al
    Regular use of aspirin and other non-steroidal anti-inflammatory drugs and breast cancer risk for women at familial or genetic risk: a cohort study.
    Breast Cancer Res. 2019;21:52.
    PubMed     Abstract available

  158. SAMAVAT H, Xun X, Jin A, Wang R, et al
    Association between prediagnostic leukocyte telomere length and breast cancer risk: the Singapore Chinese Health Study.
    Breast Cancer Res. 2019;21:50.
    PubMed     Abstract available

  159. SHIEH Y, Scott CG, Jensen MR, Norman AD, et al
    Body mass index, mammographic density, and breast cancer risk by estrogen receptor subtype.
    Breast Cancer Res. 2019;21:48.
    PubMed     Abstract available

  160. BRAVACCINI S, Maltoni R
    CD68, CD163, and matrix metalloproteinase 9 (MMP-9) in breast tumor microenvironment to predict breast cancer survival: are they enough?
    Breast Cancer Res. 2019;21:49.

    March 2019
  161. FALSTIE-JENSEN AM, Kjaersgaard A, Lorenzen EL, Jensen JD, et al
    Hypothyroidism and the risk of breast cancer recurrence and all-cause mortality - a Danish population-based study.
    Breast Cancer Res. 2019;21:44.
    PubMed     Abstract available

  162. KENNEDY SP, Han JZR, Portman N, Nobis M, et al
    Targeting promiscuous heterodimerization overcomes innate resistance to ERBB2 dimerization inhibitors in breast cancer.
    Breast Cancer Res. 2019;21:43.
    PubMed     Abstract available

  163. CLENDENEN TV, Ge W, Koenig KL, Afanasyeva Y, et al
    Breast cancer risk prediction in women aged 35-50 years: impact of including sex hormone concentrations in the Gail model.
    Breast Cancer Res. 2019;21:42.
    PubMed     Abstract available

  164. ECKER BL, Lee JY, Sterner CJ, Solomon AC, et al
    Impact of obesity on breast cancer recurrence and minimal residual disease.
    Breast Cancer Res. 2019;21:41.
    PubMed     Abstract available

  165. FORTNER RT, Sisti J, Chai B, Collins LC, et al
    Parity, breastfeeding, and breast cancer risk by hormone receptor status and molecular phenotype: results from the Nurses' Health Studies.
    Breast Cancer Res. 2019;21:40.
    PubMed     Abstract available

  166. CHIA SKL, Martin M, Holmes FA, Ejlertsen B, et al
    PIK3CA alterations and benefit with neratinib: analysis from the randomized, double-blind, placebo-controlled, phase III ExteNET trial.
    Breast Cancer Res. 2019;21:39.
    PubMed     Abstract available

  167. HRUSKA CB, Hunt KN, Conners AL, Geske JR, et al
    Impact of short-term low-dose tamoxifen on molecular breast imaging background parenchymal uptake: a pilot study.
    Breast Cancer Res. 2019;21:38.
    PubMed     Abstract available

  168. VIJAY GV, Zhao N, Den Hollander P, Toneff MJ, et al
    GSK3beta regulates epithelial-mesenchymal transition and cancer stem cell properties in triple-negative breast cancer.
    Breast Cancer Res. 2019;21:37.
    PubMed     Abstract available

  169. ALZUBI MA, Turner TH, Olex AL, Sohal SS, et al
    Separation of breast cancer and organ microenvironment transcriptomes in metastases.
    Breast Cancer Res. 2019;21:36.
    PubMed     Abstract available

  170. GARCIA-ESTEVEZ L, Moreno-Bueno G
    Updating the role of obesity and cholesterol in breast cancer.
    Breast Cancer Res. 2019;21:35.
    PubMed     Abstract available

    February 2019
  171. LUNDBERG A, Lindstrom LS, Li J, Harrell JC, et al
    The long-term prognostic and predictive capacity of cyclin D1 gene amplification in 2305 breast tumours.
    Breast Cancer Res. 2019;21:34.
    PubMed     Abstract available

  172. MCLEAN K, Darcey E, Cadby G, Lund H, et al
    The distribution and determinants of mammographic density measures in Western Australian aboriginal women.
    Breast Cancer Res. 2019;21:33.
    PubMed     Abstract available

  173. MORTIMER J, Di Palma J, Schmid K, Ye Y, et al
    Patterns of occurrence and implications of neratinib-associated diarrhea in patients with HER2-positive breast cancer: analyses from the randomized phase III ExteNET trial.
    Breast Cancer Res. 2019;21:32.
    PubMed     Abstract available

  174. KOLB AD, Shupp AB, Mukhopadhyay D, Marini FC, et al
    Osteoblasts are "educated" by crosstalk with metastatic breast cancer cells in the bone tumor microenvironment.
    Breast Cancer Res. 2019;21:31.
    PubMed     Abstract available

  175. KENSLER KH, Regan MM, Heng YJ, Baker GM, et al
    Prognostic and predictive value of androgen receptor expression in postmenopausal women with estrogen receptor-positive breast cancer: results from the Breast International Group Trial 1-98.
    Breast Cancer Res. 2019;21:30.
    PubMed     Abstract available

  176. CAO W, Li J, Hao Q, Vadgama JV, et al
    AMP-activated protein kinase: a potential therapeutic target for triple-negative breast cancer.
    Breast Cancer Res. 2019;21:29.
    PubMed     Abstract available

  177. VAN BERCKELAER C, Rypens C, van Dam P, Pouillon L, et al
    Infiltrating stromal immune cells in inflammatory breast cancer are associated with an improved outcome and increased PD-L1 expression.
    Breast Cancer Res. 2019;21:28.
    PubMed     Abstract available

  178. GREER YE, Gilbert SF, Gril B, Narwal R, et al
    MEDI3039, a novel highly potent tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) receptor 2 agonist, causes regression of orthotopic tumors and inhibits outgrowth of metastatic triple-negative breast cancer.
    Breast Cancer Res. 2019;21:27.
    PubMed     Abstract available

  179. EMI M, Kim R, Tanabe K, Uchida Y, et al
    Correction to: Targeted therapy against Bcl-2-related proteins in breast cancer cells.
    Breast Cancer Res. 2019;21:26.
    PubMed     Abstract available

  180. NGUYEN B, Venet D, Lambertini M, Desmedt C, et al
    Imprint of parity and age at first pregnancy on the genomic landscape of subsequent breast cancer.
    Breast Cancer Res. 2019;21:25.
    PubMed     Abstract available

  181. WHITE AJ, Weinberg CR, O'Meara ES, Sandler DP, et al
    Airborne metals and polycyclic aromatic hydrocarbons in relation to mammographic breast density.
    Breast Cancer Res. 2019;21:24.
    PubMed     Abstract available

  182. HSU YL, Yen MC, Chang WA, Tsai PH, et al
    CXCL17-derived CD11b(+)Gr-1(+) myeloid-derived suppressor cells contribute to lung metastasis of breast cancer through platelet-derived growth factor-BB.
    Breast Cancer Res. 2019;21:23.
    PubMed     Abstract available

  183. SMITH NG, Gyanchandani R, Shah OS, Gurda GT, et al
    Targeted mutation detection in breast cancer using MammaSeq.
    Breast Cancer Res. 2019;21:22.
    PubMed     Abstract available

  184. RODRIGUEZ-MARTINEZ A, de Miguel-Perez D, Ortega FG, Garcia-Puche JL, et al
    Exosomal miRNA profile as complementary tool in the diagnostic and prediction of treatment response in localized breast cancer under neoadjuvant chemotherapy.
    Breast Cancer Res. 2019;21:21.
    PubMed     Abstract available

  185. SCHWARZENBACHER D, Klec C, Pasculli B, Cerk S, et al
    MiR-1287-5p inhibits triple negative breast cancer growth by interaction with phosphoinositide 3-kinase CB, thereby sensitizing cells for PI3Kinase inhibitors.
    Breast Cancer Res. 2019;21:20.
    PubMed     Abstract available

    January 2019
  186. WANG DY, Gendoo DMA, Ben-David Y, Woodgett JR, et al
    A subgroup of microRNAs defines PTEN-deficient, triple-negative breast cancer patients with poorest prognosis and alterations in RB1, MYC, and Wnt signaling.
    Breast Cancer Res. 2019;21:18.
    PubMed     Abstract available

  187. GAMPENRIEDER SP, Peer A, Weismann C, Meissnitzer M, et al
    Radiologic complete response (rCR) in contrast-enhanced magnetic resonance imaging (CE-MRI) after neoadjuvant chemotherapy for early breast cancer predicts recurrence-free survival but not pathologic complete response (pCR).
    Breast Cancer Res. 2019;21:19.
    PubMed     Abstract available

  188. BHAT K, Sandler K, Duhachek-Muggy S, Alli C, et al
    Serum erythropoietin levels, breast cancer and breast cancer-initiating cells.
    Breast Cancer Res. 2019;21:17.
    PubMed     Abstract available

  189. XIAO Y, Xia J, Li L, Ke Y, et al
    Associations between dietary patterns and the risk of breast cancer: a systematic review and meta-analysis of observational studies.
    Breast Cancer Res. 2019;21:16.
    PubMed     Abstract available

  190. FLEMING RM, Fleming MR, Chaudhuri TK, Dooley WC, et al
    Letter to the Editor: A response to Hruska's case study on molecular breast imaging and the need for true tissue quantification.
    Breast Cancer Res. 2019;21:15.

  191. GHAFFARI A, Hoskin V, Turashvili G, Varma S, et al
    Intravital imaging reveals systemic ezrin inhibition impedes cancer cell migration and lymph node metastasis in breast cancer.
    Breast Cancer Res. 2019;21:12.
    PubMed     Abstract available

  192. NOKIN MJ, Bellier J, Durieux F, Peulen O, et al
    Methylglyoxal, a glycolysis metabolite, triggers metastasis through MEK/ERK/SMAD1 pathway activation in breast cancer.
    Breast Cancer Res. 2019;21:11.
    PubMed     Abstract available

  193. STRAND F, Azavedo E, Hellgren R, Humphreys K, et al
    Localized mammographic density is associated with interval cancer and large breast cancer: a nested case-control study.
    Breast Cancer Res. 2019;21:8.
    PubMed     Abstract available

  194. CAMILIO KA, Wang MY, Mauseth B, Waagene S, et al
    Combining the oncolytic peptide LTX-315 with doxorubicin demonstrates therapeutic potential in a triple-negative breast cancer model.
    Breast Cancer Res. 2019;21:9.
    PubMed     Abstract available

  195. JARMAN EJ, Ward C, Turnbull AK, Martinez-Perez C, et al
    HER2 regulates HIF-2alpha and drives an increased hypoxic response in breast cancer.
    Breast Cancer Res. 2019;21:10.
    PubMed     Abstract available

  196. LEHUEDE C, Li X, Dauvillier S, Vaysse C, et al
    Adipocytes promote breast cancer resistance to chemotherapy, a process amplified by obesity: role of the major vault protein (MVP).
    Breast Cancer Res. 2019;21:7.
    PubMed     Abstract available

  197. KIJEWSKA M, Viski C, Turrell F, Fitzpatrick A, et al
    Using an in-vivo syngeneic spontaneous metastasis model identifies ID2 as a promoter of breast cancer colonisation in the brain.
    Breast Cancer Res. 2019;21:4.
    PubMed     Abstract available

  198. HOFFMAN J, Fejerman L, Hu D, Huntsman S, et al
    Identification of novel common breast cancer risk variants at the 6q25 locus among Latinas.
    Breast Cancer Res. 2019;21:3.
    PubMed     Abstract available

  199. GAO C, Xiao G, Piersigilli A, Gou J, et al
    Context-dependent roles of MDMX (MDM4) and MDM2 in breast cancer proliferation and circulating tumor cells.
    Breast Cancer Res. 2019;21:5.
    PubMed     Abstract available

  200. SELLI C, Turnbull AK, Pearce DA, Li A, et al
    Molecular changes during extended neoadjuvant letrozole treatment of breast cancer: distinguishing acquired resistance from dormant tumours.
    Breast Cancer Res. 2019;21:2.
    PubMed     Abstract available

    December 2018
  201. HUDSON S, Vik Hjerkind K, Vinnicombe S, Allen S, et al
    Adjusting for BMI in analyses of volumetric mammographic density and breast cancer risk.
    Breast Cancer Res. 2018;20:156.
    PubMed     Abstract available

  202. NICKSON C, Procopio P, Velentzis LS, Carr S, et al
    Prospective validation of the NCI Breast Cancer Risk Assessment Tool (Gail Model) on 40,000 Australian women.
    Breast Cancer Res. 2018;20:155.
    PubMed     Abstract available

  203. WU WY, Tornberg S, Elfstrom KM, Liu X, et al
    Overdiagnosis in the population-based organized breast cancer screening program estimated by a non-homogeneous multi-state model: a cohort study using individual data with long-term follow-up.
    Breast Cancer Res. 2018;20:153.
    PubMed     Abstract available

  204. BHARDWAJ A, Singh H, Trinidad CM, Albarracin CT, et al
    The isomiR-140-3p-regulated mevalonic acid pathway as a potential target for prevention of triple negative breast cancer.
    Breast Cancer Res. 2018;20:150.
    PubMed     Abstract available

  205. BROOKS JD, Comen EA, Reiner AS, Orlow I, et al
    CYP2D6 phenotype, tamoxifen, and risk of contralateral breast cancer in the WECARE Study.
    Breast Cancer Res. 2018;20:149.
    PubMed     Abstract available

  206. KUS K, Kij A, Zakrzewska A, Jasztal A, et al
    Alterations in arginine and energy metabolism, structural and signalling lipids in metastatic breast cancer in mice detected in plasma by targeted metabolomics and lipidomics.
    Breast Cancer Res. 2018;20:148.
    PubMed     Abstract available

    November 2018
  207. MERINO VF, Cho S, Nguyen N, Sadik H, et al
    Induction of cell cycle arrest and inflammatory genes by combined treatment with epigenetic, differentiating, and chemotherapeutic agents in triple-negative breast cancer.
    Breast Cancer Res. 2018;20:145.
    PubMed     Abstract available

  208. WEGE AK, Chittka D, Buchholz S, Klinkhammer-Schalke M, et al
    HER4 expression in estrogen receptor-positive breast cancer is associated with decreased sensitivity to tamoxifen treatment and reduced overall survival of postmenopausal women.
    Breast Cancer Res. 2018;20:139.
    PubMed     Abstract available

  209. VETTER M, Landin J, Szczerba BM, Castro-Giner F, et al
    Denosumab treatment is associated with the absence of circulating tumor cells in patients with breast cancer.
    Breast Cancer Res. 2018;20:141.
    PubMed     Abstract available

  210. FRISK G, Ekberg S, Lidbrink E, Eloranta S, et al
    No association between low-dose aspirin use and breast cancer outcomes overall: a Swedish population-based study.
    Breast Cancer Res. 2018;20:142.
    PubMed     Abstract available

  211. CHATTERJEE G, Pai T, Hardiman T, Avery-Kiejda K, et al
    Molecular patterns of cancer colonisation in lymph nodes of breast cancer patients.
    Breast Cancer Res. 2018;20:143.
    PubMed     Abstract available

  212. LEECH AO, Vellanki SH, Rutherford EJ, Keogh A, et al
    Cleavage of the extracellular domain of junctional adhesion molecule-A is associated with resistance to anti-HER2 therapies in breast cancer settings.
    Breast Cancer Res. 2018;20:140.
    PubMed     Abstract available

  213. BECKWITT CH, Brufsky A, Oltvai ZN, Wells A, et al
    Statin drugs to reduce breast cancer recurrence and mortality.
    Breast Cancer Res. 2018;20:144.
    PubMed     Abstract available

  214. RHOST S, Hughes E, Harrison H, Rafnsdottir S, et al
    Sortilin inhibition limits secretion-induced progranulin-dependent breast cancer progression and cancer stem cell expansion.
    Breast Cancer Res. 2018;20:137.
    PubMed     Abstract available

  215. VAN DER WILLIK KD, Koppelmans V, Hauptmann M, Compter A, et al
    Inflammation markers and cognitive performance in breast cancer survivors 20 years after completion of chemotherapy: a cohort study.
    Breast Cancer Res. 2018;20:135.
    PubMed     Abstract available

  216. RAMIN C, May BJ, Roden RBS, Orellana MM, et al
    Evaluation of osteopenia and osteoporosis in younger breast cancer survivors compared with cancer-free women: a prospective cohort study.
    Breast Cancer Res. 2018;20:134.
    PubMed     Abstract available

  217. SUCHANSKI J, Grzegrzolka J, Owczarek T, Pasikowski P, et al
    Sulfatide decreases the resistance to stress-induced apoptosis and increases P-selectin-mediated adhesion: a two-edged sword in breast cancer progression.
    Breast Cancer Res. 2018;20:133.
    PubMed     Abstract available

  218. HOPPER JL, Dite GS, MacInnis RJ, Liao Y, et al
    Age-specific breast cancer risk by body mass index and familial risk: prospective family study cohort (ProF-SC).
    Breast Cancer Res. 2018;20:132.
    PubMed     Abstract available

    October 2018
  219. MCKNIGHT BN, Viola-Villegas NT
    Monitoring Src status after dasatinib treatment in HER2+ breast cancer with (89)Zr-trastuzumab PET imaging.
    Breast Cancer Res. 2018;20:130.
    PubMed     Abstract available

  220. LIU X, Cao M, Palomares M, Wu X, et al
    Metastatic breast cancer cells overexpress and secrete miR-218 to regulate type I collagen deposition by osteoblasts.
    Breast Cancer Res. 2018;20:127.
    PubMed     Abstract available

    Ribociclib for the first-line treatment of advanced hormone receptor-positive breast cancer: a review of subgroup analyses from the MONALEESA-2 trial.
    Breast Cancer Res. 2018;20:123.
    PubMed     Abstract available

  222. DIELI-CONWRIGHT CM, Courneya KS, Demark-Wahnefried W, Sami N, et al
    Aerobic and resistance exercise improves physical fitness, bone health, and quality of life in overweight and obese breast cancer survivors: a randomized controlled trial.
    Breast Cancer Res. 2018;20:124.
    PubMed     Abstract available

  223. BORGEN E, Rypdal MC, Sosa MS, Renolen A, et al
    NR2F1 stratifies dormant disseminated tumor cells in breast cancer patients.
    Breast Cancer Res. 2018;20:120.
    PubMed     Abstract available

  224. ANDERSEN ZJ, Jorgensen JT, Elsborg L, Lophaven SN, et al
    Long-term exposure to road traffic noise and incidence of breast cancer: a cohort study.
    Breast Cancer Res. 2018;20:119.
    PubMed     Abstract available

  225. SWERDLOW AJ, Wright LB, Schoemaker MJ, Jones ME, et al
    Maternal breast cancer risk in relation to birthweight and gestation of her offspring.
    Breast Cancer Res. 2018;20:110.
    PubMed     Abstract available

  226. UNGERLEIDER NA, Rao SG, Shahbandi A, Yee D, et al
    Breast cancer survival predicted by TP53 mutation status differs markedly depending on treatment.
    Breast Cancer Res. 2018;20:115.
    PubMed     Abstract available

  227. SETHURAMAN A, Brown M, Krutilina R, Wu ZH, et al
    BHLHE40 confers a pro-survival and pro-metastatic phenotype to breast cancer cells by modulating HBEGF secretion.
    Breast Cancer Res. 2018;20:117.
    PubMed     Abstract available

    September 2018
  228. YANG L, Tian Y, Leong WS, Song H, et al
    Efficient and tumor-specific knockdown of MTDH gene attenuates paclitaxel resistance of breast cancer cells both in vivo and in vitro.
    Breast Cancer Res. 2018;20:113.
    PubMed     Abstract available

  229. ABUBAKAR M, Sung H, Bcr D, Guida J, et al
    Breast cancer risk factors, survival and recurrence, and tumor molecular subtype: analysis of 3012 women from an indigenous Asian population.
    Breast Cancer Res. 2018;20:114.
    PubMed     Abstract available

  230. GAO P, Wang X, Jin Y, Hu W, et al
    Nogo-B receptor increases the resistance to tamoxifen in estrogen receptor-positive breast cancer cells.
    Breast Cancer Res. 2018;20:112.
    PubMed     Abstract available

  231. SCHOFFSKI P, Cresta S, Mayer IA, Wildiers H, et al
    A phase Ib study of pictilisib (GDC-0941) in combination with paclitaxel, with and without bevacizumab or trastuzumab, and with letrozole in advanced breast cancer.
    Breast Cancer Res. 2018;20:109.
    PubMed     Abstract available

  232. ROSATO RR, Davila-Gonzalez D, Choi DS, Qian W, et al
    Evaluation of anti-PD-1-based therapy against triple-negative breast cancer patient-derived xenograft tumors engrafted in humanized mouse models.
    Breast Cancer Res. 2018;20:108.
    PubMed     Abstract available

  233. BOUSQUENAUD M, Fico F, Solinas G, Ruegg C, et al
    Obesity promotes the expansion of metastasis-initiating cells in breast cancer.
    Breast Cancer Res. 2018;20:104.
    PubMed     Abstract available

  234. LEONTOVICH AA, Jalalirad M, Salisbury JL, Mills L, et al
    NOTCH3 expression is linked to breast cancer seeding and distant metastasis.
    Breast Cancer Res. 2018;20:105.
    PubMed     Abstract available

  235. DU T, Sikora MJ, Levine KM, Tasdemir N, et al
    Key regulators of lipid metabolism drive endocrine resistance in invasive lobular breast cancer.
    Breast Cancer Res. 2018;20:106.
    PubMed     Abstract available

  236. BUUS R, Yeo B, Brentnall AR, Klintman M, et al
    Novel 18-gene signature for predicting relapse in ER-positive, HER2-negative breast cancer.
    Breast Cancer Res. 2018;20:103.
    PubMed     Abstract available

  237. WU J, Li X, Teng X, Rubin DL, et al
    Magnetic resonance imaging and molecular features associated with tumor-infiltrating lymphocytes in breast cancer.
    Breast Cancer Res. 2018;20:101.
    PubMed     Abstract available

    August 2018
  238. HUTCHESON IR, Knowlden JM, Hiscox SE, Barrow D, et al
    Correction to: Heregulin beta1 drives gefitinib-resistant growth and invasion in tamoxifen-resistant MCF-7 breast cancer cells.
    Breast Cancer Res. 2018;20:98.
    PubMed     Abstract available

  239. DA CRUZ RS, Carney EJ, Clarke J, Cao H, et al
    Paternal malnutrition programs breast cancer risk and tumor metabolism in offspring.
    Breast Cancer Res. 2018;20:99.
    PubMed     Abstract available

  240. SHAIK AN, Ruterbusch JJ, Abdulfatah E, Shrestha R, et al
    Breast fibroadenomas are not associated with increased breast cancer risk in an African American contemporary cohort of women with benign breast disease.
    Breast Cancer Res. 2018;20:91.
    PubMed     Abstract available

  241. ORTEGA-OLVERA C, Ulloa-Aguirre A, Angeles-Llerenas A, Mainero-Ratchelous FE, et al
    Thyroid hormones and breast cancer association according to menopausal status and body mass index.
    Breast Cancer Res. 2018;20:94.
    PubMed     Abstract available

  242. BIERMANN J, Parris TZ, Nemes S, Danielsson A, et al
    Clonal relatedness in tumour pairs of breast cancer patients.
    Breast Cancer Res. 2018;20:96.
    PubMed     Abstract available

  243. KATCHMAN BA, Tolgay Ocal I, Cunliffe HE, Chang YH, et al
    Correction to: Expression of quiescin sulfhydryl oxidase 1 is associated with a highly invasive phenotype and correlates with a poor prognosis in luminal B breast cancer.
    Breast Cancer Res. 2018;20:89.
    PubMed     Abstract available

  244. PENKERT J, Schmidt G, Hofmann W, Schubert S, et al
    Breast cancer patients suggestive of Li-Fraumeni syndrome: mutational spectrum, candidate genes, and unexplained heredity.
    Breast Cancer Res. 2018;20:87.
    PubMed     Abstract available

  245. LIANG X, Vacher S, Boulai A, Bernard V, et al
    Targeted next-generation sequencing identifies clinically relevant somatic mutations in a large cohort of inflammatory breast cancer.
    Breast Cancer Res. 2018;20:88.
    PubMed     Abstract available

  246. SMEDA M, Kieronska A, Adamski MG, Proniewski B, et al
    Nitric oxide deficiency and endothelial-mesenchymal transition of pulmonary endothelium in the progression of 4T1 metastatic breast cancer in mice.
    Breast Cancer Res. 2018;20:86.
    PubMed     Abstract available

  247. POGUE BW
    Can novel technologies improve breast conserving surgery?
    Breast Cancer Res. 2018;20:85.

  248. DE ROON M, May AM, McTiernan A, Scholten RJPM, et al
    Effect of exercise and/or reduced calorie dietary interventions on breast cancer-related endogenous sex hormones in healthy postmenopausal women.
    Breast Cancer Res. 2018;20:81.
    PubMed     Abstract available

  249. DIAMOND JR, Eckhardt SG, Pitts TM, van Bokhoven A, et al
    A phase II clinical trial of the Aurora and angiogenic kinase inhibitor ENMD-2076 for previously treated, advanced, or metastatic triple-negative breast cancer.
    Breast Cancer Res. 2018;20:82.
    PubMed     Abstract available

    July 2018
  250. ASANO A, Ueda S, Kuji I, Yamane T, et al
    Intracellular hypoxia measured by (18)F-fluoromisonidazole positron emission tomography has prognostic impact in patients with estrogen receptor-positive breast cancer.
    Breast Cancer Res. 2018;20:78.
    PubMed     Abstract available

  251. JENSEN MB, Laenkholm AV, Nielsen TO, Eriksen JO, et al
    The Prosigna gene expression assay and responsiveness to adjuvant cyclophosphamide-based chemotherapy in premenopausal high-risk patients with breast cancer.
    Breast Cancer Res. 2018;20:79.
    PubMed     Abstract available

  252. LI JT, Wang LF, Zhao YL, Yang T, et al
    Retraction Note: Nuclear factor of activated T cells 5 maintained by Hotair suppression of miR-568 upregulates S100 calcium binding protein A4 to promote breast cancer metastasis.
    Breast Cancer Res. 2018;20:77.
    PubMed     Abstract available

  253. SHINDE A, Wilmanski T, Chen H, Teegarden D, et al
    Pyruvate carboxylase supports the pulmonary tropism of metastatic breast cancer.
    Breast Cancer Res. 2018;20:76.
    PubMed     Abstract available

  254. PAPADAKI C, Stratigos M, Markakis G, Spiliotaki M, et al
    Circulating microRNAs in the early prediction of disease recurrence in primary breast cancer.
    Breast Cancer Res. 2018;20:72.
    PubMed     Abstract available

  255. O'BRIEN KM, Sandler DP, Xu Z, Kinyamu HK, et al
    Vitamin D, DNA methylation, and breast cancer.
    Breast Cancer Res. 2018;20:70.
    PubMed     Abstract available

  256. SHAPIRA M, Kakiashvili E, Rosenberg T, Hershko DD, et al
    Correction to: The mTOR inhibitor rapamycin down-regulates the expression of the ubiquitin ligase subunit Skp2 in breast cancer cells.
    Breast Cancer Res. 2018;20:68.
    PubMed     Abstract available

  257. SJOSTROM M, Staaf J, Eden P, Warnberg F, et al
    Identification and validation of single-sample breast cancer radiosensitivity gene expression predictors.
    Breast Cancer Res. 2018;20:64.
    PubMed     Abstract available

  258. CHANG XZ, Li DQ, Hou YF, Wu J, et al
    Correction to: Identification of the functional role of peroxiredoxin 6 in the progression of breast cancer.
    Breast Cancer Res. 2018;20:63.
    PubMed     Abstract available

    June 2018
  259. DIECI MV, Tsvetkova V, Orvieto E, Piacentini F, et al
    Immune characterization of breast cancer metastases: prognostic implications.
    Breast Cancer Res. 2018;20:62.
    PubMed     Abstract available

  260. LIM KT, Cosgrave N, Hill AD, Young LS, et al
    Correction to: Nongenomic oestrogen signalling in oestrogen receptor negative breast cancer cells: a role for the angiotensin II receptor AT1.
    Breast Cancer Res. 2018;20:61.
    PubMed     Abstract available

  261. SUROV A, Clauser P, Chang YW, Li L, et al
    Can diffusion-weighted imaging predict tumor grade and expression of Ki-67 in breast cancer? A multicenter analysis.
    Breast Cancer Res. 2018;20:58.
    PubMed     Abstract available

  262. DONZELLI S, Milano E, Pruszko M, Sacconi A, et al
    Expression of ID4 protein in breast cancer cells induces reprogramming of tumour-associated macrophages.
    Breast Cancer Res. 2018;20:59.
    PubMed     Abstract available

  263. ALVES CL, Elias D, Lyng MB, Bak M, et al
    SNAI2 upregulation is associated with an aggressive phenotype in fulvestrant-resistant breast cancer cells and is an indicator of poor response to endocrine therapy in estrogen receptor-positive metastatic breast cancer.
    Breast Cancer Res. 2018;20:60.
    PubMed     Abstract available

  264. ZHU Q, Tannenbaum S, Kurtzman SH, DeFusco P, et al
    Identifying an early treatment window for predicting breast cancer response to neoadjuvant chemotherapy using immunohistopathology and hemoglobin parameters.
    Breast Cancer Res. 2018;20:56.
    PubMed     Abstract available

  265. SEVINSKY CJ, Khan F, Kokabee L, Darehshouri A, et al
    NDRG1 regulates neutral lipid metabolism in breast cancer cells.
    Breast Cancer Res. 2018;20:55.
    PubMed     Abstract available

  266. JIN K, Pandey NB, Popel AS
    Simultaneous blockade of IL-6 and CCL5 signaling for synergistic inhibition of triple-negative breast cancer growth and metastasis.
    Breast Cancer Res. 2018;20:54.
    PubMed     Abstract available

  267. GILES ED, Jindal S, Wellberg EA, Schedin T, et al
    Metformin inhibits stromal aromatase expression and tumor progression in a rodent model of postmenopausal breast cancer.
    Breast Cancer Res. 2018;20:50.
    PubMed     Abstract available

  268. NORTON N, Fox N, McCarl CA, Tenner KS, et al
    Generation of HER2-specific antibody immunity during trastuzumab adjuvant therapy associates with reduced relapse in resected HER2 breast cancer.
    Breast Cancer Res. 2018;20:52.
    PubMed     Abstract available

  269. KRIKKEN E, Khlebnikov V, Zaiss M, Jibodh RA, et al
    Amide chemical exchange saturation transfer at 7 T: a possible biomarker for detecting early response to neoadjuvant chemotherapy in breast cancer patients.
    Breast Cancer Res. 2018;20:51.
    PubMed     Abstract available

  270. TAWARA K, Bolin C, Koncinsky J, Kadaba S, et al
    OSM potentiates preintravasation events, increases CTC counts, and promotes breast cancer metastasis to the lung.
    Breast Cancer Res. 2018;20:53.
    PubMed     Abstract available

  271. LEWIS-WAMBI JS, Kim HR, Wambi C, Patel R, et al
    Correction to: Buthionine sulfoximine sensitizes antihormone-resistant human breast cancer cells to estrogen-induced apoptosis.
    Breast Cancer Res. 2018;20:57.
    PubMed     Abstract available

  272. WANG C, Brentnall AR, Cuzick J, Harkness EF, et al
    Exploring the prediction performance for breast cancer risk based on volumetric mammographic density at different thresholds.
    Breast Cancer Res. 2018;20:49.
    PubMed     Abstract available

  273. LARSSON AM, Jansson S, Bendahl PO, Levin Tykjaer Jorgensen C, et al
    Longitudinal enumeration and cluster evaluation of circulating tumor cells improve prognostication for patients with newly diagnosed metastatic breast cancer in a prospective observational trial.
    Breast Cancer Res. 2018;20:48.
    PubMed     Abstract available

  274. RIBAS R, Pancholi S, Rani A, Schuster E, et al
    Targeting tumour re-wiring by triple blockade of mTORC1, epidermal growth factor, and oestrogen receptor signalling pathways in endocrine-resistant breast cancer.
    Breast Cancer Res. 2018;20:44.
    PubMed     Abstract available

  275. PAPANASTASIOU AD, Sirinian C, Kalofonos HP
    Correction to: Identification of novel human RANK isoforms generated through alternative splicing. Implications in breast cancer cell survival and migration.
    Breast Cancer Res. 2018;20:47.
    PubMed     Abstract available

  276. BENSEN JT, Graff M, Young KL, Sethupathy P, et al
    A survey of microRNA single nucleotide polymorphisms identifies novel breast cancer susceptibility loci in a case-control, population-based study of African-American women.
    Breast Cancer Res. 2018;20:45.
    PubMed     Abstract available

  277. HRUSKA CB, Geske JR, Swanson TN, Mammel AN, et al
    Quantitative background parenchymal uptake on molecular breast imaging and breast cancer risk: a case-control study.
    Breast Cancer Res. 2018;20:46.
    PubMed     Abstract available

    May 2018
  278. JOHNSTON AN, Bu W, Hein S, Garcia S, et al
    Hyperprolactinemia-inducing antipsychotics increase breast cancer risk by activating JAK-STAT5 in precancerous lesions.
    Breast Cancer Res. 2018;20:42.
    PubMed     Abstract available

  279. ALLOUCHERY V, Beaussire L, Perdrix A, Sefrioui D, et al
    Circulating ESR1 mutations at the end of aromatase inhibitor adjuvant treatment and after relapse in breast cancer patients.
    Breast Cancer Res. 2018;20:40.
    PubMed     Abstract available

  280. KISH JK, Ward MA, Garofalo D, Ahmed HV, et al
    Real-world evidence analysis of palbociclib prescribing patterns for patients with advanced/metastatic breast cancer treated in community oncology practice in the USA one year post approval.
    Breast Cancer Res. 2018;20:37.
    PubMed     Abstract available

  281. CHEN BT, Sethi SK, Jin T, Patel SK, et al
    Assessing brain volume changes in older women with breast cancer receiving adjuvant chemotherapy: a brain magnetic resonance imaging pilot study.
    Breast Cancer Res. 2018;20:38.
    PubMed     Abstract available

  282. WANDERS JOP, van Gils CH, Karssemeijer N, Holland K, et al
    The combined effect of mammographic texture and density on breast cancer risk: a cohort study.
    Breast Cancer Res. 2018;20:36.
    PubMed     Abstract available

  283. PADUA MB, Bhat-Nakshatri P, Anjanappa M, Prasad MS, et al
    Dependence receptor UNC5A restricts luminal to basal breast cancer plasticity and metastasis.
    Breast Cancer Res. 2018;20:35.
    PubMed     Abstract available

    April 2018
  284. HOUGHTON LC, Knight JA, De Souza MJ, Goldberg M, et al
    Comparison of methods to assess onset of breast development in the LEGACY Girls Study: methodological considerations for studies of breast cancer.
    Breast Cancer Res. 2018;20:33.
    PubMed     Abstract available

  285. GOORTS B, Dreuning KMA, Houwers JB, Kooreman LFS, et al
    MRI-based response patterns during neoadjuvant chemotherapy can predict pathological (complete) response in patients with breast cancer.
    Breast Cancer Res. 2018;20:34.
    PubMed     Abstract available

  286. CAMPA D, Barrdahl M, Santoro A, Severi G, et al
    Mitochondrial DNA copy number variation, leukocyte telomere length, and breast cancer risk in the European Prospective Investigation into Cancer and Nutrition (EPIC) study.
    Breast Cancer Res. 2018;20:29.
    PubMed     Abstract available

  287. LIU WS, Chan SH, Chang HT, Li GC, et al
    Isocitrate dehydrogenase 1-snail axis dysfunction significantly correlates with breast cancer prognosis and regulates cell invasion ability.
    Breast Cancer Res. 2018;20:25.
    PubMed     Abstract available

  288. WEISS A, Bashour SI, Hess K, Thompson AM, et al
    Effect of neoadjuvant chemotherapy regimen on relapse-free survival among patients with breast cancer achieving a pathologic complete response: an early step in the de-escalation of neoadjuvant chemotherapy.
    Breast Cancer Res. 2018;20:27.
    PubMed     Abstract available

  289. CHEN J, Wu X, Christos PJ, Formenti S, et al
    Practice patterns and outcomes for patients with node-negative hormone receptor-positive breast cancer and intermediate 21-gene Recurrence Scores.
    Breast Cancer Res. 2018;20:26.
    PubMed     Abstract available

  290. CABRERA RM, Mao SPH, Surve CR, Condeelis JS, et al
    A novel neuregulin - jagged1 paracrine loop in breast cancer transendothelial migration.
    Breast Cancer Res. 2018;20:24.
    PubMed     Abstract available

    March 2018
  291. TANG YC, Ho SC, Tan E, Ng AWT, et al
    Functional genomics identifies specific vulnerabilities in PTEN-deficient breast cancer.
    Breast Cancer Res. 2018;20:22.
    PubMed     Abstract available

  292. EL ANSARI R, Craze ML, Miligy I, Diez-Rodriguez M, et al
    The amino acid transporter SLC7A5 confers a poor prognosis in the highly proliferative breast cancer subtypes and is a key therapeutic target in luminal B tumours.
    Breast Cancer Res. 2018;20:21.
    PubMed     Abstract available

  293. FROELUNDE AS, Ohlenbusch M, Hansen KB, Jessen N, et al
    Murine breast cancer feed arteries are thin-walled with reduced alpha1A-adrenoceptor expression and attenuated sympathetic vasocontraction.
    Breast Cancer Res. 2018;20:20.
    PubMed     Abstract available

  294. KNIGHT JA, Blackmore KM, Fan J, Malone KE, et al
    The association of mammographic density with risk of contralateral breast cancer and change in density with treatment in the WECARE study.
    Breast Cancer Res. 2018;20:23.
    PubMed     Abstract available

  295. ZEIDAN B, Manousopoulou A, Garay-Baquero DJ, White CH, et al
    Increased circulating resistin levels in early-onset breast cancer patients of normal body mass index correlate with lymph node negative involvement and longer disease free survival: a multi-center POSH cohort serum proteomics study.
    Breast Cancer Res. 2018;20:19.
    PubMed     Abstract available

  296. WANG X, Huang Y, Li L, Dai H, et al
    Assessment of performance of the Gail model for predicting breast cancer risk: a systematic review and meta-analysis with trial sequential analysis.
    Breast Cancer Res. 2018;20:18.
    PubMed     Abstract available

  297. BOYD N, Berman H, Zhu J, Martin LJ, et al
    The origins of breast cancer associated with mammographic density: a testable biological hypothesis.
    Breast Cancer Res. 2018;20:17.
    PubMed     Abstract available

  298. KIM H, Lin Q, Glazer PM, Yun Z, et al
    The hypoxic tumor microenvironment in vivo selects the cancer stem cell fate of breast cancer cells.
    Breast Cancer Res. 2018;20:16.
    PubMed     Abstract available

    February 2018
  299. SCHMIDT M, Weyer-Elberich V, Hengstler JG, Heimes AS, et al
    Prognostic impact of CD4-positive T cell subsets in early breast cancer: a study based on the FinHer trial patient population.
    Breast Cancer Res. 2018;20:15.
    PubMed     Abstract available

  300. ALLOTT EH, Geradts J, Cohen SM, Khoury T, et al
    Frequency of breast cancer subtypes among African American women in the AMBER consortium.
    Breast Cancer Res. 2018;20:12.
    PubMed     Abstract available

  301. ROXANIS I, Colling R, Kartsonaki C, Green AR, et al
    The significance of tumour microarchitectural features in breast cancer prognosis: a digital image analysis.
    Breast Cancer Res. 2018;20:11.
    PubMed     Abstract available

    January 2018
  302. ANNIS MG, Ouellet V, Rennhack JP, L'Esperance S, et al
    Integrin-uPAR signaling leads to FRA-1 phosphorylation and enhanced breast cancer invasion.
    Breast Cancer Res. 2018;20:9.
    PubMed     Abstract available

  303. WEBER-LASSALLE N, Hauke J, Ramser J, Richters L, et al
    BRIP1 loss-of-function mutations confer high risk for familial ovarian cancer, but not familial breast cancer.
    Breast Cancer Res. 2018;20:7.
    PubMed     Abstract available

  304. YANG H, He W, Eriksson M, Li J, et al
    Inherited factors contribute to an inverse association between preeclampsia and breast cancer.
    Breast Cancer Res. 2018;20:6.
    PubMed     Abstract available

  305. MA H, Ursin G, Xu X, Lee E, et al
    Body mass index at age 18 years and recent body mass index in relation to risk of breast cancer overall and ER/PR/HER2-defined subtypes in white women and African-American women: a pooled analysis.
    Breast Cancer Res. 2018;20:5.
    PubMed     Abstract available

  306. BUSBY J, Mills K, Zhang SD, Liberante FG, et al
    Selective serotonin reuptake inhibitor use and breast cancer survival: a population-based cohort study.
    Breast Cancer Res. 2018;20:4.
    PubMed     Abstract available

  307. LI N, Rowley SM, Thompson ER, McInerny S, et al
    Evaluating the breast cancer predisposition role of rare variants in genes associated with low-penetrance breast cancer risk SNPs.
    Breast Cancer Res. 2018;20:3.
    PubMed     Abstract available

  308. HUSS L, Butt ST, Almgren P, Borgquist S, et al
    SNPs related to vitamin D and breast cancer risk: a case-control study.
    Breast Cancer Res. 2018;20:1.
    PubMed     Abstract available

  309. PILLAI SG, Li S, Siddappa CM, Ellis MJ, et al
    Identifying biomarkers of breast cancer micrometastatic disease in bone marrow using a patient-derived xenograft mouse model.
    Breast Cancer Res. 2018;20:2.
    PubMed     Abstract available

    December 2017
  310. THOMSEN AML, Pedersen AB, Kristensen NR, Moller BK, et al
    Use of prescription drugs and risk of postoperative red blood cell transfusion in breast cancer patients: a Danish population-based cohort study.
    Breast Cancer Res. 2017;19:135.
    PubMed     Abstract available

  311. LI HY, Liang JL, Kuo YL, Lee HH, et al
    miR-105/93-3p promotes chemoresistance and circulating miR-105/93-3p acts as a diagnostic biomarker for triple negative breast cancer.
    Breast Cancer Res. 2017;19:133.
    PubMed     Abstract available

  312. PARADA H JR, Sun X, Fleming JM, Williams-DeVane CR, et al
    Race-associated biological differences among luminal A and basal-like breast cancers in the Carolina Breast Cancer Study.
    Breast Cancer Res. 2017;19:131.
    PubMed     Abstract available

  313. YU J, Qin B, Moyer AM, Sinnwell JP, et al
    Establishing and characterizing patient-derived xenografts using pre-chemotherapy percutaneous biopsy and post-chemotherapy surgical samples from a prospective neoadjuvant breast cancer study.
    Breast Cancer Res. 2017;19:130.
    PubMed     Abstract available

    November 2017
  314. HELLAND T, Henne N, Bifulco E, Naume B, et al
    Serum concentrations of active tamoxifen metabolites predict long-term survival in adjuvantly treated breast cancer patients.
    Breast Cancer Res. 2017;19:125.
    PubMed     Abstract available

  315. JONES ME, Schoemaker MJ, Wright LB, Ashworth A, et al
    Smoking and risk of breast cancer in the Generations Study cohort.
    Breast Cancer Res. 2017;19:118.
    PubMed     Abstract available

  316. BAGEGNI N, Thomas S, Liu N, Luo J, et al
    Serum thymidine kinase 1 activity as a pharmacodynamic marker of cyclin-dependent kinase 4/6 inhibition in patients with early-stage breast cancer receiving neoadjuvant palbociclib.
    Breast Cancer Res. 2017;19:123.
    PubMed     Abstract available

  317. HROMAS R, Kim HS, Sidhu G, Williamson E, et al
    The endonuclease EEPD1 mediates synthetic lethality in RAD52-depleted BRCA1 mutant breast cancer cells.
    Breast Cancer Res. 2017;19:122.
    PubMed     Abstract available

  318. AMANATULLAH DF, Tamaresis JS, Chu P, Bachmann MH, et al
    Local estrogen axis in the human bone microenvironment regulates estrogen receptor-positive breast cancer cells.
    Breast Cancer Res. 2017;19:121.
    PubMed     Abstract available

  319. OHNSTAD HO, Borgen E, Falk RS, Lien TG, et al
    Prognostic value of PAM50 and risk of recurrence score in patients with early-stage breast cancer with long-term follow-up.
    Breast Cancer Res. 2017;19:120.
    PubMed     Abstract available

  320. BROUCKAERT O, Rudolph A, Laenen A, Keeman R, et al
    Reproductive profiles and risk of breast cancer subtypes: a multi-center case-only study.
    Breast Cancer Res. 2017;19:119.
    PubMed     Abstract available

    October 2017
  321. BERNHARDT S, Bayerlova M, Vetter M, Wachter A, et al
    Proteomic profiling of breast cancer metabolism identifies SHMT2 and ASCT2 as prognostic factors.
    Breast Cancer Res. 2017;19:112.
    PubMed     Abstract available

  322. TU CF, Wu MY, Lin YC, Kannagi R, et al
    FUT8 promotes breast cancer cell invasiveness by remodeling TGF-beta receptor core fucosylation.
    Breast Cancer Res. 2017;19:111.
    PubMed     Abstract available

    September 2017
  323. PELEKANOU V, Carvajal-Hausdorf DE, Altan M, Wasserman B, et al
    Erratum to: Effect of neoadjuvant chemotherapy on tumor-infiltrating lymphocytes and PD-L1 expression in breast cancer and its clinical significance.
    Breast Cancer Res. 2017;19:109.

    May 2017
  324. BRAMAN NM, Etesami M, Prasanna P, Dubchuk C, et al
    Intratumoral and peritumoral radiomics for the pretreatment prediction of pathological complete response to neoadjuvant chemotherapy based on breast DCE-MRI.
    Breast Cancer Res. 2017;19:57.
    PubMed     Abstract available

  325. SAMENI M, Cavallo-Medved D, Franco OE, Chalasani A, et al
    Pathomimetic avatars reveal divergent roles of microenvironment in invasive transition of ductal carcinoma in situ.
    Breast Cancer Res. 2017;19:56.
    PubMed     Abstract available

    March 2017
  326. ELSHOF LE, Schaapveld M, Rutgers EJ, Schmidt MK, et al
    The method of detection of ductal carcinoma in situ has no therapeutic implications: results of a population-based cohort study.
    Breast Cancer Res. 2017;19:26.
    PubMed     Abstract available

  327. UBELLACKER JM, Haider MT, DeCristo MJ, Allocca G, et al
    Zoledronic acid alters hematopoiesis and generates breast tumor-suppressive bone marrow cells.
    Breast Cancer Res. 2017;19:23.
    PubMed     Abstract available

    February 2017
  328. SCHOEMAKER MJ, Jones ME, Allen S, Hoare J, et al
    Childhood body size and pubertal timing in relation to adult mammographic density phenotype.
    Breast Cancer Res. 2017;19:13.
    PubMed     Abstract available

  329. TER BRAAK B, Siezen CL, Lee JS, Rao P, et al
    Insulin-like growth factor 1 receptor activation promotes mammary gland tumor development by increasing glycolysis and promoting biomass production.
    Breast Cancer Res. 2017;19:14.
    PubMed     Abstract available

    January 2017
  330. BARCUS CE, O'Leary KA, Brockman JL, Rugowski DE, et al
    Elevated collagen-I augments tumor progressive signals, intravasation and metastasis of prolactin-induced estrogen receptor alpha positive mammary tumor cells.
    Breast Cancer Res. 2017;19:9.
    PubMed     Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Breast Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.